IONS Ionis Pharmaceuticals, Inc.
$43.96▲ +1.24%
Healthcare
Other
After hours
$43.99▲ +0.07%
Oct 27, 4:40 PM ET
Volume 2.38M
Avg Volume (10D) 2.82M
Key Metrics & Fundamentals
Market Cap
$7.31B
P/E Ratio
–
Div Yield
0.00%
52W Range
42.08 - 86.74
% vs 50 MA
-11.99%
% vs 200 MA
-34.70%
RSI-14
44.2
MACD Histogram
+0.4400
Beta (1Y vs SPY)
0.50
Free Cash Flow
$547.30M
Gross Rev
$267.95M
Gross Profit
$265.21M
EBITDA
-$95.29M
COGS
$2.74M
Operating Exp
$367.51M
Operating Income
-$102.30M
EBIT
-$102.30M
Pretax Income
-$113.38M
Net Income
-$114.65M
EPS (Diluted)
-0.69
Price & Volume History
Loading chart…
Recent News
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Zacks · Oct 27, 2026 10:49 AM ET
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Business Wire · Oct 23, 2026 1:37 PM ET
Ionis ranked #1 on Science’s Top Employers list
Business Wire · Oct 22, 2026 2:25 PM ET
Ionis Pharmaceuticals Secures FDA Orphan Drug Designation For Rare Epilepsy Treatment
Stocktwits · Oct 22, 2026 2:00 PM ET
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform From Market Perform
MT Newswires · Oct 22, 2026 7:43 AM ET
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
BioPharma Dive · Oct 21, 2026 12:03 PM ET
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)
Business Wire · Oct 20, 2026 9:20 PM ET
Severe Hypertriglyceridemia Market Set for Growth During the Forecast Period (2026-2036) Following Approval of Ionis' TRYNGOLZA and Emergence of Novel Therapies | DelveInsight
PR Newswire · Oct 20, 2026 10:31 AM ET
Ionis Pharmaceuticals Receives Approval Recommendation for Tryngolza's Indication Expansion in EU
MT Newswires · Oct 16, 2026 7:06 AM ET
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Business Wire · Oct 16, 2026 6:45 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See IONS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.